Rosiglitazone does not raise heart risk in diabetes

07/23/2013 | MedPage Today (free registration)

Rosiglitazone did not appear to increase the risk of major cardiac events and death in diabetes patients with coronary artery disease compared with patients not taking a thiazolidinedione-based drug, according to an analysis in the journal Circulation. Researchers also found a lower incidence of the composite of death, myocardial infarction and stroke in patients taking rosiglitazone.

View Full Article in:

MedPage Today (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA